Zenas BioPharma, Inc.
ZBIO
$25.87
$1.204.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 8.47% | 61.97% | |||
| Gross Profit | -8.47% | -61.97% | |||
| SG&A Expenses | 8.46% | 18.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.47% | 49.88% | |||
| Operating Income | -8.47% | -49.88% | |||
| Income Before Tax | 66.30% | -366.68% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 66.32% | -366.89% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 66.32% | -366.89% | |||
| EBIT | -8.47% | -49.88% | |||
| EBITDA | -8.47% | -49.89% | |||
| EPS Basic | 67.91% | -271.40% | |||
| Normalized Basic EPS | -4.75% | -26.03% | |||
| EPS Diluted | 67.91% | -271.40% | |||
| Normalized Diluted EPS | -4.75% | -26.03% | |||
| Average Basic Shares Outstanding | 4.95% | 25.71% | |||
| Average Diluted Shares Outstanding | 4.95% | 25.71% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||